HK Stock Market Move | Pharmaron Beijing (03759) surged more than 4%, with a 42.5% year-on-year increase in net profit attributable to shareholders in the third quarter. The company also raised its full-year revenue growth guidance.

Pharmaron Beijing (03759) rose more than 4%, up 4.09% at the time of publication, to HK$25.98, with a turnover of HK$4.08 billion. In terms of news, Pharmaron Beijing released its performance for the first three quarters of 2025. The group achieved operating income of RMB 10.86 billion, an increase of 14.38% year-on-year; net profit attributable to shareholders of listed companies was RMB 1.41 billion, a decrease of 19.76% year-on-year. Looking at the third quarter alone, the company achieved revenue of RMB 3.64 billion, an increase of 13.4% year-on-year, and net profit attributable to shareholders of RMB 4.4 billion, an increase of 42.5% year-on-year. The announcement stated that in the first three quarters of 2025, the company's newly signed orders increased by more than 13% year-on-year. Among them, the new orders in the laboratory services sector increased by more than 12% year-on-year, and the new orders in the CMC (small molecule CDMO) services sector increased by approximately 20% year-on-year. Based on the new signed orders and business trends, the company expects the full-year revenue in 2025 to increase by 12%-16% year-on-year (compared to the previous estimate of 10-15%). Furthermore, Pharmaron Beijing announced that on October 28, the company entered into an agreement with the shareholders of Bai Ao De (including Kang Junningyuan, Kang Junzhongyuan, and Yufeng Investment). The company agreed to acquire and the shareholders of Bai Ao De agreed to sell 82.54% of Bai Ao De's shares, with a total consideration of approximately RMB 1.346 billion. After the completion of this acquisition, Bai Ao De will be directly held by the company with 82.54% of the shares, thus becoming a subsidiary of the company. Pharmaron Beijing stated that this acquisition will help supplement the company's technical platform and service capabilities in structural biology, complex drug target protein preparation and analysis, forming a good synergy with the company's existing business platform and customer service capabilities.